ANI Pharmaceuticals’ (ANIP) Buy Rating Reiterated at HC Wainwright

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $94.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 50.42% from the company’s previous close.

ANIP has been the topic of a number of other research reports. Guggenheim upped their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price objective for the company. Finally, Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $79.75.

ANI Pharmaceuticals Stock Up 1.7 %

ANIP stock opened at $62.49 on Monday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The stock’s 50 day simple moving average is $58.40 and its 200 day simple moving average is $58.06. The company has a market cap of $1.36 billion, a P/E ratio of -113.62 and a beta of 0.63.

Insider Transactions at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,700 shares of company stock valued at $610,201. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ANIP. Thrivent Financial for Lutherans increased its position in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after buying an additional 299 shares during the period. Exchange Traded Concepts LLC raised its holdings in ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after acquiring an additional 310 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock valued at $582,000 after purchasing an additional 364 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after acquiring an additional 412 shares during the period. Finally, Natixis Advisors LLC lifted its position in ANI Pharmaceuticals by 2.3% during the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock valued at $1,028,000 after purchasing an additional 417 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.